Arcellx has filed a notice of an exempt offering of securities to raise $100,000,003.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Arcellx is raising $100,000,003.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Rami Elghandour played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Arcellx
We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies. Arcellx, Inc. (NASDAQ: ACLX) is reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. We believe that cell therapies are one of the forward pillars of medicine and our mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible.
To learn more about Arcellx, visit https://www.arcellx.com/
Contact:
Rami Elghandour, Chief Executive Officer
240-327-0603
https://www.linkedin.com/in/ramielghandour/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.